| Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. | |
| | |
MedLine Citation:
|
PMID: 11477368 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Blocking the action of interleukin (IL) 17 with an IL-17 receptor (R):Fc fusion protein inhibits T-cell proliferative responses to alloantigens and prolongs vascularized heart graft survival. In this study, we examined whether IL-17 antagonism could suppress the development of chronic rejection. METHODS: A 0.6-cm section of C57BL10 (H2b) thoracic aorta was transplanted to recipient C3H (H2k) abdominal aorta. IL-17R:Fc or control human immunoglobulin G was administered i.p. (500 microg/day) from days 0 to 6 or from days 0 to 29. Mice were killed on days 7 or 30. Grafts were examined histologically and stained for alpha-smooth muscle actin (alpha-smA). Antidonor mixed leukocyte reaction, cytotoxic T cell, and alloantibody responses were quantified. RESULTS: On day 7, control grafts showed mononuclear cell (MNC) infiltration, pronounced endothelial damage, and apoptosis of intimal and medial cell compartments. By day 30, there was concentric intimal thickening, accumulation of alpha-smA+ cells, and collagen deposition. Patchy destruction of the elastic membranes and loss of alpha-smA expression in media were evident. IL-17R:Fc for 6 days decreased MNC infiltration in the intimal and medial compartments at day 7. The endothelium was preserved (completely or partially) in all grafts. The medial compartment showed normal alpha-smA expression. Irrespective of IL-17R:Fc treatment for either 6 days or continuously, allografts harvested at day 30 showed circumferential intimal thickening, with accumulation of alpha-smA+ cells and collagen deposition. There was no effect on circulating alloantibody levels. CONCLUSIONS: These findings support a role for IL-17 in the immunopathogenesis of acute vascular rejection and demonstrate the potential of IL-17 antagonism for therapy. By contrast, IL-17 antagonism does not appear to prevent ensuing chronic graft vascular disease, in particular neointimal formation. |
| | |
Authors:
|
J L Tang; V M Subbotin; M A Antonysamy; A B Troutt; A S Rao; A W Thomson |
Related Documents
:
|
14621898 - Lysis of heart endothelial cells from donor origin by cardiac graft infiltrating cells. 15591948 - Evaluation of donor-specific transfusion sources: unique failure of bone marrow cells t... 2908098 - Mononuclear cells infiltrating kidney allografts in the absence of rejection. effect of... 12947308 - Genetic deletion of chemokine receptor cxcr3 or antibody blockade of its ligand ip-10 m... 1577068 - Origin of thymic and peritoneal ly-1 b cells. 10430328 - Presentation of t-cell-rich b-cell lymphoma mimicking acute hepatitis. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Transplantation Volume: 72 ISSN: 0041-1337 ISO Abbreviation: Transplantation Publication Date: 2001 Jul |
Date Detail:
|
Created Date: 2001-07-30 Completed Date: 2001-08-23 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0132144 Medline TA: Transplantation Country: United States |
Other Details:
|
Languages: eng Pagination: 348-50 Citation Subset: IM |
Affiliation:
|
Thomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, W1544 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA. thomsonaw@msx.upmc.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Animals Aorta, Abdominal / surgery Aorta, Thoracic / surgery, transplantation* Chronic Disease Complement System Proteins / immunology Graft Rejection / prevention & control* Humans Immunoglobulin G / pharmacology Interleukin-17 / antagonists & inhibitors, immunology* Isoantibodies / blood Mice Mice, Inbred C3H Mice, Inbred C57BL Receptors, Interleukin / therapeutic use* Recombinant Fusion Proteins / therapeutic use Transplantation, Homologous / immunology* |
| Grant Support | |
ID/Acronym/Agency:
|
DK 29961/DK/NIDDK NIH HHS; DK 49745/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulin G; 0/Interleukin-17; 0/Isoantibodies; 0/Receptors, Interleukin; 0/Recombinant Fusion Proteins; 0/rmIL-17R:huFc; 9007-36-7/Complement System Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Elevated right ventricular pressures are not a contraindication to liver transplantation in Alagille...
Next Document: Long-term islet allograft function in the absence of chronic immunosuppression: a case report of a n...